Phase 3 Parkinson's Disease Trial, Recruiting NCT06120049 Sponsor: prof. dr. Koen Van Laere Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 3 Parkinson's Disease Trial, Recruiting

NCT06120049
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Healthy volunteers (ages 18–85) may be eligible if they:

  • Are willing to give written consent to participate.
  • Are using a highly effective form of birth control.
  • Are in good general health based on medical history, physical exam, and lab tests.
  • Have no history of major neurological, mental health, or other significant medical conditions.
  • Have a normal or near-normal brain MRI scan (minor findings may be acceptable for those aged 60 and over).

People with Parkinson's Disease (ages 45–85) may be eligible if they:

  • Have a confirmed Parkinson's disease diagnosis based on recognised medical diagnostic guidelines.
  • Have had motor symptoms for either less than 5 years or 5 years or longer (two separate groups are being studied).
  • Have had a previous brain scan (PET or SPECT) that showed abnormal results related to dopamine function.
  • Are able to understand the study information and provide written consent.

People with Multiple System Atrophy – Parkinsonian type (MSA-P, ages 45–85) may be eligible if they:

  • Have a confirmed or probable MSA-P diagnosis based on recognised medical diagnostic guidelines.
  • Have had a previous brain scan (PET or SPECT) that showed abnormal results related to dopamine function.
  • Are able to understand the study information and provide written consent.

People with Alzheimer's Disease dementia (ages 50–85) may be eligible if they:

  • Have a diagnosis of probable Alzheimer's disease with supporting evidence of the disease process.
  • Are able to understand the study information and provide written consent.

People with Dementia with Lewy Bodies (ages 50–85) may be eligible if they:

  • Have a diagnosis of probable Dementia with Lewy Bodies.
  • Have had a previous brain scan (PET or SPECT) that showed abnormal results related to dopamine function.
  • Are able to understand the study information and provide written consent.

Who may not be able to join:

For healthy volunteers:

  • People with major health conditions that could interfere with the study tests.
  • People with any signs of memory or thinking problems.
  • People with a history of mental health conditions.
  • People who use illegal drugs or have a history of drug or alcohol misuse.
  • People taking regular medications that could interfere with specific types of brain imaging used in this study.
  • People who have been exposed to ionising radiation (such as from other research studies) above a certain level in the past 12 months.
  • People who cannot have an MRI scan for any medical reason.
  • People with claustrophobia or who cannot tolerate being in a confined space during the scan.
  • People unwilling to avoid intense physical exercise around the time of the study.
  • People who are pregnant or breastfeeding.
  • People who do not agree to have unexpected findings from their scan shared with their GP.
  • People with a failed Allen test (a blood flow check) or an allergy to a local anaesthetic called lidocaine — this applies only to those agreeing to an optional blood sampling procedure.

For people with Parkinson's Disease, MSA-P, Alzheimer's Disease, or Dementia with Lewy Bodies:

  • People with neurological or psychiatric conditions other than their primary diagnosis.
  • People with significant other health conditions, particularly diabetes or heart disease.
  • People with a certain level of white matter changes or other notable abnormalities on their brain MRI scan (confirm with trial site).
  • People with a history of alcohol or drug misuse.
  • People who have previously taken part in research studies involving radiation exposure.
  • People who cannot have an MRI scan for any medical reason.
  • People with claustrophobia or who cannot tolerate being in a confined space during scanning.
  • People unwilling to avoid intense physical exercise around the time of the study.
  • People who are pregnant or breastfeeding.
  • People who do not agree to have unexpected findings from their scan shared with their GP.
  • People taking blood-thinning medications (anticoagulants).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Koen Van Laere, Professor at KULeuven, department head of nuclear medicine at UZ Leuven

Phone: +3216343715

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
prof. dr. Koen Van Laere
Registry
ClinicalTrials.gov
Start date
19 January 2024
Est. completion
1 July 2026

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Difference in diagnostic accuracy between [18F]-MFBG and [I123]-MIBG

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov